U
Enlighta Inc.
NLTAH.V
TSX
Recommendation
--
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
--
E
Sell
3/4/2019Downgrade
HooXi Network Inc. (HXI.V) was downgraded to E+ from D- on 3/4/2019 due to a decline in the growth index, efficiency index and volatility index. Operating cash flow declined 647.79% from $223.5 to -$1.22M, EBIT declined 377.82% from -$161.4 to -$771.2, and net income declined 342.63% from -$161.4 to -$714.4.
HooXi Network Inc. (HXI.V) was downgraded to E+ from D- on 3/4/2019 due to a decline in the growth index, efficiency index and volatility index. Operating cash flow declined 647.79% from $223.5 to -$1.22M, EBIT declined 377.82% from -$161.4 to -$771.2, and net income declined 342.63% from -$161.4 to -$714.4.
D
Sell
11/29/2018Downgrade
Liberty Biopharma Inc. (LTY.V) was downgraded to D- from D on 11/29/2018 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0253 to -$0.5708, and EBIT declined 12.77% from -$267.1 to -$301.2.
Liberty Biopharma Inc. (LTY.V) was downgraded to D- from D on 11/29/2018 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0253 to -$0.5708, and EBIT declined 12.77% from -$267.1 to -$301.2.
D
Sell
8/6/2018Upgraded
Liberty Biopharma Inc. (LTY.V) was upgraded to D from D- on 8/6/2018 due to an increase in the total return index and volatility index.
Liberty Biopharma Inc. (LTY.V) was upgraded to D from D- on 8/6/2018 due to an increase in the total return index and volatility index.
D
Sell
7/20/2018Downgrade
Liberty Biopharma Inc. (LTY.V) was downgraded to D- from D on 7/20/2018 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 0.5 to 0.12.
Liberty Biopharma Inc. (LTY.V) was downgraded to D- from D on 7/20/2018 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 0.5 to 0.12.
D
Sell
3/16/2018Upgraded
Liberty Biopharma Inc. (LTY.V) was upgraded to D from D- on 3/16/2018 due to an increase in the solvency index, valuation index and volatility index.
Liberty Biopharma Inc. (LTY.V) was upgraded to D from D- on 3/16/2018 due to an increase in the solvency index, valuation index and volatility index.
D
Sell
6/5/2017Downgrade
Liberty Biopharma Inc. (LTY.V) was downgraded to D- from D on 6/5/2017 due to a substantial decline in the efficiency index and valuation index. Net income declined 54.69% from -$213.4 to -$330.1, and total capital declined 10.3% from $2.96M to $2.65M.
Liberty Biopharma Inc. (LTY.V) was downgraded to D- from D on 6/5/2017 due to a substantial decline in the efficiency index and valuation index. Net income declined 54.69% from -$213.4 to -$330.1, and total capital declined 10.3% from $2.96M to $2.65M.
D
Sell
5/31/2017Upgraded
Liberty Biopharma Inc. (LTY.V) was upgraded to D from E+ on 5/31/2017 due to a significant increase in the efficiency index, valuation index and total return index. Total capital increased 1,113.63% from $243.6 to $2.96M, and net income increased 1.2% from -$216 to -$213.4.
Liberty Biopharma Inc. (LTY.V) was upgraded to D from E+ on 5/31/2017 due to a significant increase in the efficiency index, valuation index and total return index. Total capital increased 1,113.63% from $243.6 to $2.96M, and net income increased 1.2% from -$216 to -$213.4.
E
Sell
5/31/2016Downgrade
Avagenesis Corp. (VVA.V) was downgraded to E+ from D- on 5/31/2016 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.55 to 0.14, and total capital declined 17.66% from $671.1 to $552.6.
Avagenesis Corp. (VVA.V) was downgraded to E+ from D- on 5/31/2016 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.55 to 0.14, and total capital declined 17.66% from $671.1 to $552.6.
D
Sell
3/11/2016Downgrade
Avagenesis Corp. (VVA.V) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.08 to 0.55.
Avagenesis Corp. (VVA.V) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.08 to 0.55.
D
Sell
5/20/2015Upgraded
Avagenesis Corp. (VVA.V) was upgraded to D from D- on 5/20/2015 due to an increase in the solvency index, growth index and valuation index. EBIT increased 247.08% from -$169.5 to -$588.3, earnings per share increased from -$0.0032 to -$0.0081, and operating cash flow increased 106.11% from -$258.5 to -$532.8.
Avagenesis Corp. (VVA.V) was upgraded to D from D- on 5/20/2015 due to an increase in the solvency index, growth index and valuation index. EBIT increased 247.08% from -$169.5 to -$588.3, earnings per share increased from -$0.0032 to -$0.0081, and operating cash flow increased 106.11% from -$258.5 to -$532.8.
D
Sell
3/31/2015Downgrade
Avagenesis Corp. (VVA.V) was downgraded to D- from D on 3/31/2015 due to a substantial decline in the volatility index.
Avagenesis Corp. (VVA.V) was downgraded to D- from D on 3/31/2015 due to a substantial decline in the volatility index.
D
Sell
2/18/2015Upgraded
Avagenesis Corp. (VVA.V) was upgraded to D from D- on 2/18/2015 due to an increase in the volatility index and efficiency index.
Avagenesis Corp. (VVA.V) was upgraded to D from D- on 2/18/2015 due to an increase in the volatility index and efficiency index.
D
Sell
11/7/2014Upgraded
Avagenesis Corp. (VVA.V) was upgraded to D- from E+ on 11/7/2014 due to an increase in the volatility index, total return index and growth index. Operating cash flow increased 35.9% from -$734.5 to -$998.2.
Avagenesis Corp. (VVA.V) was upgraded to D- from E+ on 11/7/2014 due to an increase in the volatility index, total return index and growth index. Operating cash flow increased 35.9% from -$734.5 to -$998.2.
E
Sell
6/2/2014Upgraded
Avagenesis Corp. (VVA.V) was upgraded to E+ from E on 6/2/2014 due to a major increase in the total return index, volatility index and growth index. EBIT increased 71.17% from -$484.5 to -$829.3, and operating cash flow increased 15.92% from -$633.6 to -$734.5.
Avagenesis Corp. (VVA.V) was upgraded to E+ from E on 6/2/2014 due to a major increase in the total return index, volatility index and growth index. EBIT increased 71.17% from -$484.5 to -$829.3, and operating cash flow increased 15.92% from -$633.6 to -$734.5.
E
Sell
3/28/2014Upgraded
Avagenesis Corp. (VVA.V) was upgraded to E from E- on 3/28/2014 due to an increase in the total return index and volatility index.
Avagenesis Corp. (VVA.V) was upgraded to E from E- on 3/28/2014 due to an increase in the total return index and volatility index.
E
Sell
3/18/2014Upgraded
Avagenesis Corp. (VVA.V) was upgraded to E- from on 3/18/2014 due to a significant increase in the solvency index, volatility index and growth index. Operating cash flow increased 263.93% from -$174.1 to -$633.6, earnings per share increased from -$0.0103 to -$0.0327, and the quick ratio increased from 3.79 to 7.45.
Avagenesis Corp. (VVA.V) was upgraded to E- from on 3/18/2014 due to a significant increase in the solvency index, volatility index and growth index. Operating cash flow increased 263.93% from -$174.1 to -$633.6, earnings per share increased from -$0.0103 to -$0.0327, and the quick ratio increased from 3.79 to 7.45.
